Xin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xin Wang has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Zhizhong Shang
The First Clinical Medical College of Lanzhou University, Lanzhou, China
12 shared publicationsMingchuan Wang
The First Clinical Medical College of Lanzhou University, Lanzhou, China
10 shared publicationsBaolin Zhang
The First Clinical Medical College of Lanzhou University, Lanzhou, China
9 shared publicationsJinlei Chen
The First Clinical Medical School of Lanzhou University, Lanzhou, China
6 shared publicationsPingping Wanyan
Department of Pathology and Pathophysiology, School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou, China; The Second Hospital of Lanzhou University, Lanzhou, China
6 shared publicationsDongliang Li
The First Clinical Medical School of Lanzhou University, Lanzhou, China
4 shared publications
Latest Publications
- 3 September 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 951
Robot-assisted surgery for degenerative lumbar spine diseases: a disease-specific bibliometric and knowledge-mapping analysis
- 3 September 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 951
Robot-assisted surgery for degenerative lumbar spine diseases: a disease-specific bibliometric and knowledge-mapping analysis
- 5 June 2026
- Published by Springer Nature in Spinal Cord
- p. 1-8
Dual evidence reveals the therapeutic efficacy of exosome-delivered miR-124-3p in spinal cord injury via a novel CTDSP1/WNT/β-catenin mechanism
Study Design Integrated preclinical systematic review and meta-analysis with basic experimental research. Objectives To evaluate the therapeutic efficacy of miR-124-3p in spinal cord injury (SCI) repair and elucidate its mechanism involving the CTDSP1/WNT/β‑catenin axis. Setting University-based laboratory in Lanzhou, China. Methods A meta‑analysis of five animal studies assessed the effects of miR‑124‑3p. In vitro, a lipopolysaccharide‑injured PC12 cell model was treated with exosomes derived from miR‑124‑3p‑overexpressing human umbilical cord mesenchymal stem cells. Mechanistic validation included dual‑luciferase reporter assay, qPCR, Western blot, and pathway inhibition/rescue experiments. Results The meta‑analysis showed that miR‑124‑3p significantly improved motor function, reduced glial scar marker GFAP and pro‑inflammatory cytokines, and increased neuronal/axonal markers (Map2, NF200, NeuN). Mechanistically, miR‑124‑3p directly targeted the 3′‑UTR of CTDSP1. Exosome‑delivered miR‑124‑3p downregulated CTDSP1, activated WNT/β‑catenin signaling, suppressed GFAP/CSPG, and promoted β‑tubulin III, NeuN, and NF200 expression. These effects were reversed by the WNT inhibitor MSAB and mimicked by a CTDSP1 inhibitor. Conclusions miR‑124‑3p promotes SCI repair primarily by targeting CTDSP1 to activate the WNT/β‑catenin pathway, thereby inhibiting glial scarring and enhancing neuronal survival/regeneration. This mechanism supports the therapeutic potential of combined exosome and miRNA strategies. The alternative text for this image may have been generated using AI.
- 5 June 2026
- Published by Springer Nature in Spinal Cord
- p. 1-8
Dual evidence reveals the therapeutic efficacy of exosome-delivered miR-124-3p in spinal cord injury via a novel CTDSP1/WNT/β-catenin mechanism
Study Design Integrated preclinical systematic review and meta-analysis with basic experimental research. Objectives To evaluate the therapeutic efficacy of miR-124-3p in spinal cord injury (SCI) repair and elucidate its mechanism involving the CTDSP1/WNT/β‑catenin axis. Setting University-based laboratory in Lanzhou, China. Methods A meta‑analysis of five animal studies assessed the effects of miR‑124‑3p. In vitro, a lipopolysaccharide‑injured PC12 cell model was treated with exosomes derived from miR‑124‑3p‑overexpressing human umbilical cord mesenchymal stem cells. Mechanistic validation included dual‑luciferase reporter assay, qPCR, Western blot, and pathway inhibition/rescue experiments. Results The meta‑analysis showed that miR‑124‑3p significantly improved motor function, reduced glial scar marker GFAP and pro‑inflammatory cytokines, and increased neuronal/axonal markers (Map2, NF200, NeuN). Mechanistically, miR‑124‑3p directly targeted the 3′‑UTR of CTDSP1. Exosome‑delivered miR‑124‑3p downregulated CTDSP1, activated WNT/β‑catenin signaling, suppressed GFAP/CSPG, and promoted β‑tubulin III, NeuN, and NF200 expression. These effects were reversed by the WNT inhibitor MSAB and mimicked by a CTDSP1 inhibitor. Conclusions miR‑124‑3p promotes SCI repair primarily by targeting CTDSP1 to activate the WNT/β‑catenin pathway, thereby inhibiting glial scarring and enhancing neuronal survival/regeneration. This mechanism supports the therapeutic potential of combined exosome and miRNA strategies. The alternative text for this image may have been generated using AI.
- Open Access
- 18 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2290
Rebuilding Mitochondrial Homeostasis and Inhibiting Ferroptosis: Therapeutic Mechanisms and Prospects for Spinal Cord Injury
During the pathological process of spinal cord injury (SCI), ferroptosis is closely related to mitochondrial homeostasis. Following the occurrence of SCI, the interruption of local blood supply leads to mitochondrial damage within cells and a reduction in Adenosine triphosphate (ATP) production. This results in the loss of transmembrane ion gradients, causing an influx of Ca2+ into the cells, which in turn generates a significant amount of Reactive oxygen species (ROS) and reactive nitrogen species. This leads to severe mitochondrial dysfunction and an imbalance in mitochondrial homeostasis. Ferroptosis is a form of programmed cell death that differs from other types of apoptosis, as it is dependent on the accumulation of iron and lipid peroxides, along with their byproducts. The double bond structures in intracellular polyunsaturated fatty acids (PUFA) are particularly susceptible to attack by ROS, leading to the formation of lipid alkyl free radicals. This accumulation of lipid peroxides within the cells triggers ferroptosis. After SCI, the triggering of ferroptosis is closely associated with the “death triangle”—a core network that catalyzes cell death through the interaction of three factors: local iron overload, collapse of antioxidant defenses, and dysregulation of PUFA metabolism (where PUFA are susceptible to attack by reactive ROS leading to lipid peroxidation). These three elements interact to form a central network driving cell death. In the pathological cascade of SCI, mitochondria serve as both a major source of ROS and a primary target of their attack, playing a crucial role in the initiation and execution of cellular ferroptosis. Mitochondrial homeostasis imbalance is not only a key inducer of the “death triangle” (such as the intensification of lipid peroxidation by mitochondrial ROS), but is also reverse-regulated by the “death triangle” (such as the destruction of mitochondrial structure by lipid peroxidation products). Through the cascade reaction of this triangular network, mitochondrial homeostasis imbalance and the “death triangle” jointly drive the progression of secondary damage. This study aims to synthesize the mechanisms by which various therapeutic approaches mitigate SCI through targeted regulation of mitochondrial homeostasis and inhibition of ferroptosis. Unlike previous research, we integrate the bidirectional regulatory relationship between “mitochondrial homeostasis disruption” and “ferroptosis” in SCI, and emphasize their importance as a synergistic therapeutic target. We not only elaborate in detail how mitochondrial homeostasis—including biogenesis, dynamics, and mitophagy—modulates the initiation and execution of ferroptosis, but also summarize recent strategies that simultaneously target both processes to achieve neuroprotection and functional recovery. Furthermore, this review highlights the translational potential of various treatments in blocking the pathological cascade driven by oxidative stress and lipid peroxidation. These insights provide a novel theoretical framework and propose combinatory therapeutic approaches, thereby laying the groundwork for designing precise and effective comprehensive treatment strategies for SCI in clinical settings.
- 18 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2290
Open AccessRebuilding Mitochondrial Homeostasis and Inhibiting Ferroptosis: Therapeutic Mechanisms and Prospects for Spinal Cord Injury
During the pathological process of spinal cord injury (SCI), ferroptosis is closely related to mitochondrial homeostasis. Following the occurrence of SCI, the interruption of local blood supply leads to mitochondrial damage within cells and a reduction in Adenosine triphosphate (ATP) production. This results in the loss of transmembrane ion gradients, causing an influx of Ca2+ into the cells, which in turn generates a significant amount of Reactive oxygen species (ROS) and reactive nitrogen species. This leads to severe mitochondrial dysfunction and an imbalance in mitochondrial homeostasis. Ferroptosis is a form of programmed cell death that differs from other types of apoptosis, as it is dependent on the accumulation of iron and lipid peroxides, along with their byproducts. The double bond structures in intracellular polyunsaturated fatty acids (PUFA) are particularly susceptible to attack by ROS, leading to the formation of lipid alkyl free radicals. This accumulation of lipid peroxides within the cells triggers ferroptosis. After SCI, the triggering of ferroptosis is closely associated with the “death triangle”—a core network that catalyzes cell death through the interaction of three factors: local iron overload, collapse of antioxidant defenses, and dysregulation of PUFA metabolism (where PUFA are susceptible to attack by reactive ROS leading to lipid peroxidation). These three elements interact to form a central network driving cell death. In the pathological cascade of SCI, mitochondria serve as both a major source of ROS and a primary target of their attack, playing a crucial role in the initiation and execution of cellular ferroptosis. Mitochondrial homeostasis imbalance is not only a key inducer of the “death triangle” (such as the intensification of lipid peroxidation by mitochondrial ROS), but is also reverse-regulated by the “death triangle” (such as the destruction of mitochondrial structure by lipid peroxidation products). Through the cascade reaction of this triangular network, mitochondrial homeostasis imbalance and the “death triangle” jointly drive the progression of secondary damage. This study aims to synthesize the mechanisms by which various therapeutic approaches mitigate SCI through targeted regulation of mitochondrial homeostasis and inhibition of ferroptosis. Unlike previous research, we integrate the bidirectional regulatory relationship between “mitochondrial homeostasis disruption” and “ferroptosis” in SCI, and emphasize their importance as a synergistic therapeutic target. We not only elaborate in detail how mitochondrial homeostasis—including biogenesis, dynamics, and mitophagy—modulates the initiation and execution of ferroptosis, but also summarize recent strategies that simultaneously target both processes to achieve neuroprotection and functional recovery. Furthermore, this review highlights the translational potential of various treatments in blocking the pathological cascade driven by oxidative stress and lipid peroxidation. These insights provide a novel theoretical framework and propose combinatory therapeutic approaches, thereby laying the groundwork for designing precise and effective comprehensive treatment strategies for SCI in clinical settings.
- Open Access
- 18 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Sulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2/SLC7A11/GPX4 signaling axis
Osteosarcoma (OS), a highly malignant primary bone tumor, is characterized by early metastasis, drug resistance, and a resultant poor prognosis, leading to significant disability and mortality. While diverse treatment modalities exist, their therapeutic efficacy remains limited, underscoring the urgent need to investigate effective targeted therapies. Sulfasalazine (SAS), a commonly used anti-inflammatory drug prescribed for nonspecific gastrointestinal diseases, autoimmune rheumatic diseases, ankylosing spondylitis, and various skin conditions, has recently garnered attention for its potential as an anti-tumor agent, specifically its ability to induce ferroptosis, a novel form of regulated cell death. This presents a promising new avenue for OS treatment. Ferroptosis plays a critical role in the malignant progression of OS by regulating iron homeostasis and oxidative stress. To explore the potential of SAS to induce ferroptosis in OS cells, we employed a combined approach of network pharmacological analysis and molecular docking simulations. Network pharmacological analysis identified significant overlap among key target genes of SAS, ferroptosis, and OS, suggesting a multifaceted mechanism of action. Molecular docking simulations further corroborated the hypothesis that SAS targets ferroptosis pathways in OS, solidifying the rationale for further investigation. Our results demonstrate that SAS significantly inhibited the proliferation and migration of OS cells, inducing apoptosis and effectively attenuating their malignant progression. Notably, SAS-treated OS cells displayed hallmarks of ferroptosis, including iron accumulation, elevated levels of malondialdehyde and reactive oxygen species, and reduced levels of glutathione and superoxide dismutase. To confirm the involvement of ferroptosis, we treated SAS-exposed OS cells with the ferroptosis inhibitors DFO, Fer-1, and Lip-1, which reversed the inhibitory effects of SAS on cell activity, further supporting the conclusion that SAS triggers ferroptosis in these cells. We additionally observed that SAS decreased mitochondrial membrane potential in OS cells, potentially indicating mitochondrial damage during ferroptosis. Mechanistically, we found that SAS induced ferroptosis by downregulating the expression of NRF2, subsequently decreasing the expression of the light chain subunit of the cysteine/glutamate transporter system Xc- (SLC7A11) and glutathione peroxidase 4. Collectively, these findings demonstrate that SAS triggers ferroptosis through the NRF2/SLC7A11/GPX4 signaling axis, thereby inhibiting the biological activity of OS cells. This research provides a strong experimental basis for the potential of SAS as a candidate drug for OS treatment and offers a novel targeted therapeutic strategy for this disease.
- 18 August 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessSulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2/SLC7A11/GPX4 signaling axis
Osteosarcoma (OS), a highly malignant primary bone tumor, is characterized by early metastasis, drug resistance, and a resultant poor prognosis, leading to significant disability and mortality. While diverse treatment modalities exist, their therapeutic efficacy remains limited, underscoring the urgent need to investigate effective targeted therapies. Sulfasalazine (SAS), a commonly used anti-inflammatory drug prescribed for nonspecific gastrointestinal diseases, autoimmune rheumatic diseases, ankylosing spondylitis, and various skin conditions, has recently garnered attention for its potential as an anti-tumor agent, specifically its ability to induce ferroptosis, a novel form of regulated cell death. This presents a promising new avenue for OS treatment. Ferroptosis plays a critical role in the malignant progression of OS by regulating iron homeostasis and oxidative stress. To explore the potential of SAS to induce ferroptosis in OS cells, we employed a combined approach of network pharmacological analysis and molecular docking simulations. Network pharmacological analysis identified significant overlap among key target genes of SAS, ferroptosis, and OS, suggesting a multifaceted mechanism of action. Molecular docking simulations further corroborated the hypothesis that SAS targets ferroptosis pathways in OS, solidifying the rationale for further investigation. Our results demonstrate that SAS significantly inhibited the proliferation and migration of OS cells, inducing apoptosis and effectively attenuating their malignant progression. Notably, SAS-treated OS cells displayed hallmarks of ferroptosis, including iron accumulation, elevated levels of malondialdehyde and reactive oxygen species, and reduced levels of glutathione and superoxide dismutase. To confirm the involvement of ferroptosis, we treated SAS-exposed OS cells with the ferroptosis inhibitors DFO, Fer-1, and Lip-1, which reversed the inhibitory effects of SAS on cell activity, further supporting the conclusion that SAS triggers ferroptosis in these cells. We additionally observed that SAS decreased mitochondrial membrane potential in OS cells, potentially indicating mitochondrial damage during ferroptosis. Mechanistically, we found that SAS induced ferroptosis by downregulating the expression of NRF2, subsequently decreasing the expression of the light chain subunit of the cysteine/glutamate transporter system Xc- (SLC7A11) and glutathione peroxidase 4. Collectively, these findings demonstrate that SAS triggers ferroptosis through the NRF2/SLC7A11/GPX4 signaling axis, thereby inhibiting the biological activity of OS cells. This research provides a strong experimental basis for the potential of SAS as a candidate drug for OS treatment and offers a novel targeted therapeutic strategy for this disease.
- Open Access
- 28 November 2024
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 15 (1) , 1-9
Mechanism and prospects of mitochondrial transplantation for spinal cord injury treatment
Spinal cord injury (SCI) involves a continuous and dynamic cascade of complex reactions, with mitochondrial damage and dysfunction-induced energy metabolism disorders playing a central role throughout the process. These disorders not only determine the severity of secondary injuries but also influence the potential for axonal regeneration. Given the critical role of energy metabolism disturbances in the pathology of SCI, strategies such as enhancing mitochondrial transport within axons to alleviate local energy deficits, or transplanting autologous or allogeneic mitochondria to restore energy supply to damaged tissues, have emerged as potential approaches for SCI repair. These strategies also aim to modulate local inflammatory responses and apoptosis. Preclinical studies have initially demonstrated that mitochondrial transplantation (MT) significantly reduces neuronal death and promotes axonal regeneration following spinal cord injury. MT achieves this by regulating signaling pathways such as MAPK/ERK and PI3K/Akt, promoting the expression of growth-associated protein-43 (GAP-43) in neurons, and inhibiting the expression of apoptosis-related proteins like Grp78, Chop, and P-Akt, thereby enhancing the survival and regeneration of damaged neurons. Additionally, MT plays a role in promoting the expression of vascular endothelial growth factor, facilitating tissue repair, and reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Furthermore, MT modulates neuronal apoptosis and inflammatory responses by decreasing the expression of p-JNK, a member of the MAPK family. In summary, by reviewing the detailed mechanisms underlying the cascade of pathological processes in SCI, we emphasize the changes in endogenous mitochondria post-SCI and the potential of exogenous MT in SCI repair. This review aims to provide insights and a basis for developing more effective clinical treatments for SCI.
- 28 November 2024
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 15 (1) , 1-9
Open AccessMechanism and prospects of mitochondrial transplantation for spinal cord injury treatment
Spinal cord injury (SCI) involves a continuous and dynamic cascade of complex reactions, with mitochondrial damage and dysfunction-induced energy metabolism disorders playing a central role throughout the process. These disorders not only determine the severity of secondary injuries but also influence the potential for axonal regeneration. Given the critical role of energy metabolism disturbances in the pathology of SCI, strategies such as enhancing mitochondrial transport within axons to alleviate local energy deficits, or transplanting autologous or allogeneic mitochondria to restore energy supply to damaged tissues, have emerged as potential approaches for SCI repair. These strategies also aim to modulate local inflammatory responses and apoptosis. Preclinical studies have initially demonstrated that mitochondrial transplantation (MT) significantly reduces neuronal death and promotes axonal regeneration following spinal cord injury. MT achieves this by regulating signaling pathways such as MAPK/ERK and PI3K/Akt, promoting the expression of growth-associated protein-43 (GAP-43) in neurons, and inhibiting the expression of apoptosis-related proteins like Grp78, Chop, and P-Akt, thereby enhancing the survival and regeneration of damaged neurons. Additionally, MT plays a role in promoting the expression of vascular endothelial growth factor, facilitating tissue repair, and reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. Furthermore, MT modulates neuronal apoptosis and inflammatory responses by decreasing the expression of p-JNK, a member of the MAPK family. In summary, by reviewing the detailed mechanisms underlying the cascade of pathological processes in SCI, we emphasize the changes in endogenous mitochondria post-SCI and the potential of exogenous MT in SCI repair. This review aims to provide insights and a basis for developing more effective clinical treatments for SCI.
- Top Cited PapersOpen Access
- 8 July 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-13
Global incidence and characteristics of spinal cord injury since 2000–2021: a systematic review and meta-analysis
Background: This study employs systematic review and meta-analysis to explore the incidence and characteristics of spinal cord injury (SCI) between 2000 and 2021, aiming to provide the most recent and comprehensive data support for the prevention, diagnosis, treatment, and care of SCI. Methods: Systematic searches were conducted on epidemiological studies of SCI published between January 1, 2000, and March 29, 2024. Meta-analysis, subgroup analysis, meta-regression, publication bias detection, and literature quality assessment were extensively utilized. Results: The pooled results from 229 studies indicated that the overall incidence rate of SCI was 23.77 (95% CI, 21.50–26.15) per million people, with traumatic spinal cord injuries (TSCI) at a rate of 26.48 (95% CI, 24.15–28.93) per million people, and non-traumatic spinal cord injuries (NTSCI) at a rate of 17.93 (95% CI, 13.30-23.26) per million people. The incidence of TSCI exhibited a marked age-related increase and was significantly higher in community settings compared to hospital and database sources. Males experienced TSCI at a rate 3.2 times higher than females. Between 2000 and 2021, the incidence of TSCI remained consistently high, between 20 and 45 per million people, whereas NTSCI incidence has seen a steady rise since 2007, stabilizing at a high rate of 25–35 per million people. Additionally, the incidence of TSCI in developing countries was notably higher than that in developed countries. There were significant differences in the causes of injury, severity, injury segments, gender, and age distribution among the TSCI and NTSCI populations, but the proportion of male patients was much higher than that of female patients. Moreover, study quality, country type, and SCI type contributed to the heterogeneity in the meta-analysis. Conclusions: The incidence rates of different types of SCI remain high, and the demographic distribution of SCI patients is changing, indicating a serious disease burden on healthcare systems and affected populations. These findings underscore the necessity of adopting targeted preventive, therapeutic, and rehabilitative measures based on the incidence and characteristics of SCI.
- 8 July 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-13
Top Cited PapersOpen AccessGlobal incidence and characteristics of spinal cord injury since 2000–2021: a systematic review and meta-analysis
Background: This study employs systematic review and meta-analysis to explore the incidence and characteristics of spinal cord injury (SCI) between 2000 and 2021, aiming to provide the most recent and comprehensive data support for the prevention, diagnosis, treatment, and care of SCI. Methods: Systematic searches were conducted on epidemiological studies of SCI published between January 1, 2000, and March 29, 2024. Meta-analysis, subgroup analysis, meta-regression, publication bias detection, and literature quality assessment were extensively utilized. Results: The pooled results from 229 studies indicated that the overall incidence rate of SCI was 23.77 (95% CI, 21.50–26.15) per million people, with traumatic spinal cord injuries (TSCI) at a rate of 26.48 (95% CI, 24.15–28.93) per million people, and non-traumatic spinal cord injuries (NTSCI) at a rate of 17.93 (95% CI, 13.30-23.26) per million people. The incidence of TSCI exhibited a marked age-related increase and was significantly higher in community settings compared to hospital and database sources. Males experienced TSCI at a rate 3.2 times higher than females. Between 2000 and 2021, the incidence of TSCI remained consistently high, between 20 and 45 per million people, whereas NTSCI incidence has seen a steady rise since 2007, stabilizing at a high rate of 25–35 per million people. Additionally, the incidence of TSCI in developing countries was notably higher than that in developed countries. There were significant differences in the causes of injury, severity, injury segments, gender, and age distribution among the TSCI and NTSCI populations, but the proportion of male patients was much higher than that of female patients. Moreover, study quality, country type, and SCI type contributed to the heterogeneity in the meta-analysis. Conclusions: The incidence rates of different types of SCI remain high, and the demographic distribution of SCI patients is changing, indicating a serious disease burden on healthcare systems and affected populations. These findings underscore the necessity of adopting targeted preventive, therapeutic, and rehabilitative measures based on the incidence and characteristics of SCI.
- 7 October 2023
- Published by Elsevier in Cytotherapy
- Vol. 26 (1) , 1-10
Stem cell-derived exosomes for traumatic spinal cord injury: a systematic review and network meta-analysis based on a rat model
- 7 October 2023
- Published by Elsevier in Cytotherapy
- Vol. 26 (1) , 1-10
Stem cell-derived exosomes for traumatic spinal cord injury: a systematic review and network meta-analysis based on a rat model
- Open Access
- 18 July 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1235324
Bibliometric analysis of stem cells for spinal cord injury: current status and emerging frontiers
Background: This study aimed to conduct a bibliometric analysis of the literature on stem cell therapy for spinal cord injury to visualize the research status, identify hotspots, and explore the development trends in this field.Methods: We searched the Web of Science Core Collection database using relevant keywords (“stem cells” and “spinal cord injury”) and retrieved the published literature between 2000 and 2022. Data such as journal title, author information, institutional affiliation, country, and keywords were extracted. Afterwards, we performed bibliometric analysis of the retrieved data using Bibliometrix, VOSviewer, and CiteSpace.Results: A total of 5375 articles related to stem cell therapy for spinal cord injury were retrieved, and both the annual publication volume and the cumulative publication volume showed an upward trend. neural regeneration research was the journal with the most publications and the fastest cumulative publication growth (162 articles), Okano Hideyuki was the author with the highest number of publications and citations (114 articles), Sun Yat-sen University was the institution with the highest number of publications (420 articles), and China was the country with the highest number of publications (5357 articles). However, different authors, institutions, and countries need to enhance their cooperation in order to promote the generation of significant academic achievements. Current research in this field has focused on stem cell transplantation, neural regeneration, motor function recovery, exosomes, and tissue engineering. Meanwhile, future research directions are primarily concerned with the molecular mechanisms, safety, clinical trials, exosomes, scaffolds, hydrogels, and inflammatory responses of stem cell therapy for spinal cord injuries.Conclusion: In summary, this study provided a comprehensive analysis of the current research status and frontiers of stem cell therapy for spinal cord injury. The findings provide a foundation for future research and clinical translation efforts of stem cell therapy in this field.
- 18 July 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1235324
Open AccessBibliometric analysis of stem cells for spinal cord injury: current status and emerging frontiers
Background: This study aimed to conduct a bibliometric analysis of the literature on stem cell therapy for spinal cord injury to visualize the research status, identify hotspots, and explore the development trends in this field.Methods: We searched the Web of Science Core Collection database using relevant keywords (“stem cells” and “spinal cord injury”) and retrieved the published literature between 2000 and 2022. Data such as journal title, author information, institutional affiliation, country, and keywords were extracted. Afterwards, we performed bibliometric analysis of the retrieved data using Bibliometrix, VOSviewer, and CiteSpace.Results: A total of 5375 articles related to stem cell therapy for spinal cord injury were retrieved, and both the annual publication volume and the cumulative publication volume showed an upward trend. neural regeneration research was the journal with the most publications and the fastest cumulative publication growth (162 articles), Okano Hideyuki was the author with the highest number of publications and citations (114 articles), Sun Yat-sen University was the institution with the highest number of publications (420 articles), and China was the country with the highest number of publications (5357 articles). However, different authors, institutions, and countries need to enhance their cooperation in order to promote the generation of significant academic achievements. Current research in this field has focused on stem cell transplantation, neural regeneration, motor function recovery, exosomes, and tissue engineering. Meanwhile, future research directions are primarily concerned with the molecular mechanisms, safety, clinical trials, exosomes, scaffolds, hydrogels, and inflammatory responses of stem cell therapy for spinal cord injuries.Conclusion: In summary, this study provided a comprehensive analysis of the current research status and frontiers of stem cell therapy for spinal cord injury. The findings provide a foundation for future research and clinical translation efforts of stem cell therapy in this field.
- Open Access
- 12 May 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10
Incidence and risk factors of deep vein thrombosis in patients with spinal cord injury: a systematic review with meta-analysis
Background: Spinal cord injury (SCI) is a highly disabling disease with huge public health burden. The complications associated with it, especially deep vein thrombosis (DVT), further aggravate the disability.Objective: To explore the incidence and risk factors of DVT after SCI, in order to provide guidance for disease prevention in the future.Methods: A search was performed on PubMed, Web of Science, Embase, and Cochrane database up to November 9, 2022. Literature screening, information extraction and quality evaluation were performed by two researchers. The data was later combined by metaprop and metan commands in STATA 16.0.Results: A total of 101 articles were included, including 223,221 patients. Meta-analysis showed that the overall incidence of DVT was 9.3% (95% CI: 8.2%–10.6%), and the incidence of DVT in patients with acute and chronic SCI was 10.9% (95% CI: 8.7%–13.2%) and 5.3% (95% CI: 2.2%–9.7%), respectively. The incidence of DVT decreased gradually with the accumulation of publication years and sample size. However, the annual incidence of DVT has increased since 2017. There are 24 kinds of risk factors that may contribute to the formation of DVT, involving multiple aspects of the baseline characteristics of the patient, biochemical indicators, severity of SCI, and comorbidities.Conclusions: The incidence of DVT after SCI is high and has been gradually increasing in recent years. Moreover, there are numerous risk factors associated with DVT. Comprehensive preventive measures need to be taken as early as possible in the future.Systematic Review Registration: www.crd.york.ac.uk/prospero, identifier CRD42022377466.
- 12 May 2023
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 10
Open AccessIncidence and risk factors of deep vein thrombosis in patients with spinal cord injury: a systematic review with meta-analysis
Background: Spinal cord injury (SCI) is a highly disabling disease with huge public health burden. The complications associated with it, especially deep vein thrombosis (DVT), further aggravate the disability.Objective: To explore the incidence and risk factors of DVT after SCI, in order to provide guidance for disease prevention in the future.Methods: A search was performed on PubMed, Web of Science, Embase, and Cochrane database up to November 9, 2022. Literature screening, information extraction and quality evaluation were performed by two researchers. The data was later combined by metaprop and metan commands in STATA 16.0.Results: A total of 101 articles were included, including 223,221 patients. Meta-analysis showed that the overall incidence of DVT was 9.3% (95% CI: 8.2%–10.6%), and the incidence of DVT in patients with acute and chronic SCI was 10.9% (95% CI: 8.7%–13.2%) and 5.3% (95% CI: 2.2%–9.7%), respectively. The incidence of DVT decreased gradually with the accumulation of publication years and sample size. However, the annual incidence of DVT has increased since 2017. There are 24 kinds of risk factors that may contribute to the formation of DVT, involving multiple aspects of the baseline characteristics of the patient, biochemical indicators, severity of SCI, and comorbidities.Conclusions: The incidence of DVT after SCI is high and has been gradually increasing in recent years. Moreover, there are numerous risk factors associated with DVT. Comprehensive preventive measures need to be taken as early as possible in the future.Systematic Review Registration: www.crd.york.ac.uk/prospero, identifier CRD42022377466.
- Open Access
- 15 April 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-17
A systematic review, umbrella review, and quality assessment on clinical translation of stem cell therapy for knee osteoarthritis: Are we there yet?
Background: The success of stem cell therapy for knee osteoarthritis (KOA) in preclinical animal models has accelerated the pace of clinical translation. However, it remains uncertain whether the current scientific evidence supports the clinical application of stem cells in treating KOA. A comprehensive evaluation of the safety and efficacy of stem cell therapies and scientific evidence quality is necessary. Methods: Using “stem cells” and “knee osteoarthritis” as the search terms, several databases, including PubMed, Web of Science, Cochrane, Embase, and Clinicaltrials.gov, were searched on August 25, 2022, and updated on February 27, 2023. Clinical studies that reported adverse reactions (ARs) of stem cell therapy in KOA patients were included without limiting the type of studies. Quantitative systematic reviews of stem cell therapy for KOA that conducted meta-analysis were included. Two researchers conducted literature screening and data extraction independently, and the evidence quality was evaluated according to the Institute of Health Economics and AMSTAR 2 criteria. Results: Fifty clinical studies and 13 systematic reviews/meta-analyses (SRs/MAs) were included. Nineteen ARs were reported in 50 studies, including five knee-related ARs, seven common ARs, and seven other ARs. Some studies reported over 10% prevalence of knee pain (24.5%; 95% CI [14.7%, 35.7%]), knee effusion (12.5%; 95% CI [4.8%, 22.5%]), and knee swelling (11.9%; 95% CI [3.5%, 23.5%]). Additionally, two studies have reported cases of prostate cancer and breast tumors, respectively. However, these two studies suggest that stem cell therapy does not bring significant ARs to patients. SRs/MAs results revealed that stem cell therapy relieved pain in patients over time but did not improve knee function. However, current clinical studies have limited evidence regarding study objectives, test designs, and patient populations. Similarly, SRs/MAs have inadequate evidence regarding study design, risk of bias assessment, outcome description, comprehensive discussion, and potential conflicts of interest. Conclusions: The inefficacy of stem cells, the risk of potential complications, and the limited quality of evidence from current studies precluded any recommendation for using stem cell products in patients with KOA. Clinical translation of stem cell therapies remains baseless and should be cautiously approached until more robust evidence is available. PROSPERO registration number: CRD42022355875.
- 15 April 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-17
Open AccessA systematic review, umbrella review, and quality assessment on clinical translation of stem cell therapy for knee osteoarthritis: Are we there yet?
Background: The success of stem cell therapy for knee osteoarthritis (KOA) in preclinical animal models has accelerated the pace of clinical translation. However, it remains uncertain whether the current scientific evidence supports the clinical application of stem cells in treating KOA. A comprehensive evaluation of the safety and efficacy of stem cell therapies and scientific evidence quality is necessary. Methods: Using “stem cells” and “knee osteoarthritis” as the search terms, several databases, including PubMed, Web of Science, Cochrane, Embase, and Clinicaltrials.gov, were searched on August 25, 2022, and updated on February 27, 2023. Clinical studies that reported adverse reactions (ARs) of stem cell therapy in KOA patients were included without limiting the type of studies. Quantitative systematic reviews of stem cell therapy for KOA that conducted meta-analysis were included. Two researchers conducted literature screening and data extraction independently, and the evidence quality was evaluated according to the Institute of Health Economics and AMSTAR 2 criteria. Results: Fifty clinical studies and 13 systematic reviews/meta-analyses (SRs/MAs) were included. Nineteen ARs were reported in 50 studies, including five knee-related ARs, seven common ARs, and seven other ARs. Some studies reported over 10% prevalence of knee pain (24.5%; 95% CI [14.7%, 35.7%]), knee effusion (12.5%; 95% CI [4.8%, 22.5%]), and knee swelling (11.9%; 95% CI [3.5%, 23.5%]). Additionally, two studies have reported cases of prostate cancer and breast tumors, respectively. However, these two studies suggest that stem cell therapy does not bring significant ARs to patients. SRs/MAs results revealed that stem cell therapy relieved pain in patients over time but did not improve knee function. However, current clinical studies have limited evidence regarding study objectives, test designs, and patient populations. Similarly, SRs/MAs have inadequate evidence regarding study design, risk of bias assessment, outcome description, comprehensive discussion, and potential conflicts of interest. Conclusions: The inefficacy of stem cells, the risk of potential complications, and the limited quality of evidence from current studies precluded any recommendation for using stem cell products in patients with KOA. Clinical translation of stem cell therapies remains baseless and should be cautiously approached until more robust evidence is available. PROSPERO registration number: CRD42022355875.